Influenza virus vaccine quadrivalent - Medicago

Drug Profile

Influenza virus vaccine quadrivalent - Medicago

Alternative Names: Quadrivalent seasonal influenza VLP vaccine - Medicago; Seasonal influenza vaccine quadrivalent - Medicago; Seasonal influenza virus-like particle (VLP) vaccine - Medicago

Latest Information Update: 24 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Medicago
  • Class Influenza virus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Influenza virus infections

Most Recent Events

  • 20 Jul 2017 Phase-III clinical trials in Influenza virus infections (In adults) in Finland (IM)
  • 20 Jul 2017 Phase-III clinical trials in Influenza virus infections (In adults, Prevention) in Finland (IM) (EudraCT2017-001239-38)
  • 01 Apr 2016 Medicago initiates a phase II trial for Influenza virus infections (Prevention, In the elderly) in USA and Canada (IM) (NCT02831751)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top